Eckert & Ziegler: Sales Growth and Jump in Income in First Quarter

Press release

Eckert & Ziegler: Sales Growth and Jump in Income in First Quarter

Berlin, 9 May, 2017. Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), a Berlin-based company specializing in isotope technology for medical, scientific and industrial applications, increased its sales in the first quarter of 2017 by 5 % year on year to EUR 37.6 million. Earnings per share rose to EUR 0.69 per share, increasing compared with the prior year's quarter by EUR 0.22 per share or 47 %. This value is significantly above budget. The improved financial performance is the result of lower costs and increased sales with profitable products. In line with the sales growth, the gross profit margin rose by EUR 0.4 million.

Sales in the Isotope Products segment saw a currency-related rise of 2 % in the first quarter of 2017 compared with the prior year. However, sales were supported in the prior year by a one-time demand peak in the energy sector. The absence of this non-recurring effect in the first quarter of 2017 made the continued stable sales and financial performance all the more pleasing.

By contrast, sales in the Radiation Therapy segment declined slightly by EUR 0.5 million or 6 % to EUR 6.0 million. Temporary supply difficulties of radioactive prostate implants at the beginning of the year, caused by raw material bottlenecks, were made up for during the quarter, with the result that sales are in fact currently higher than planned.

The strong growth is continuing in the Radiopharma segment. Compared with the prior year's period, sales increased EUR 1.6 million or 17 % to EUR 11.3 million. Significant sales growth was seen particularly in the U.S.

Cash flow from operating activities increased EUR 4.0 million or 513 % to EUR 4.7 million. The EUR 1.2 million higher profit for the period is crucial.

In 2017, earnings are expected to increase and could exceed EUR 2.00 per share, assuming that exchange rates remain stable and excluding acquisitions and the sale of divisions. Sales of just under EUR 150 million are expected.

The complete financial statements can be viewed here:
http://www.ezag.com/fileadmin/user_upload/ezag/investors-financial-reports/englisch/euz117e.pdf

About Eckert & Ziegler.
Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), with approximately 610 employees, is one the world's largest providers of isotope technology for radiation therapy and nuclear medicine.
Contributing to saving lives.

For further information or questions, please contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com